TAB014
AssetAlso called TAB014 Monoclonal Antibody Injection
Neutralizes VEGF-A to inhibit abnormal blood vessel growth and vascular leakage in the retina.
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Not known
- 2
- Indications
- 2
- Trials
- 2
- Developers
Trial NCT05461339 is still running. Trial NCT05461339 updated in its registry on Jan 7, 2025. clinicaltrials.gov
Indications
2Neovascular age-related macular degeneration
Phase 3, Active not recruiting, NCT05461339, clinicaltrials.gov, Oct 31, 2026
Age-related macular degeneration
Phase 1, Unknown, NCT03675880, clinicaltrials.gov, Nov 13, 2026
In the full profile
- Owner and partners3
- Trials2
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.